BOOKS BY CATEGORY
Your Account
Orphan Drugs
From Regulatory Issues to Clinical Transition
This book is not yet published – pre-order your copy now.
Price
Quantity
€140.30
(To see other currencies, click on price)
Hardback
Add to basket  

MORE ABOUT THIS BOOK

Main description:

While drug discovery for common disorders is somewhat standard and based on the large potential markets, the small market for most orphan diseases means that effective therapies are uncommon. With next generation DNA sequencing, the pace of inherited novel rare disease gene identification has increased markedly. Drug discovery for rare diseases is somewhat hampered by a lack of collaboration between academia and industry separating the necessary resources from skills. This volume discusses important aspects of orphan drug development such as regulatory affairs, public industry partnership, bench to bedside using examples of rare diseases, challenges of clinical trials and future directions.


Contents:

Introduction. Policies and Regulatory affairs. Public industry partnership. Advances in NGS and its impact on orphan drug discoveries. Example from rare disorders: SMA- from basic mechanism to phase 3 trial. Duchene Muscular Dystrophy: clinical and therapeutic overview (focusing on current drug pipeline). Other Muscular Dystrophies: Clinical overview. Hereditary Neuropathies. Amyotrophic lateral sclerosis: Current therapeutic pipeline. Familial Dysautonomia. Pamidronate for Rare bone diseases. Repurposing orphan drugs. Orphan Diseases in middle east: Clinical overview. Clinical trials for rare diseases- Lessons learned along with future directions.


PRODUCT DETAILS

ISBN-13: 9781498763073
Publisher: Productivity Press
Publication date: February, 2025
Pages: 320
Weight: 652g
Availability: Available
Subcategories: Biochemistry, General Issues, Pharmacology

CUSTOMER REVIEWS

Average Rating